The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics

被引:191
|
作者
Kang, R. [1 ]
Tang, D. [1 ]
Schapiro, N. E. [1 ]
Loux, T. [1 ]
Livesey, K. M. [1 ]
Billiar, T. R. [1 ]
Wang, H. [2 ]
Van Houten, B. [3 ]
Lotze, M. T. [1 ]
Zeh, H. J. [1 ]
机构
[1] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15219 USA
[2] NYU, Sch Med, North Shore Univ Hosp, Manhasset, NY USA
[3] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Lab Mol & Cell Biol Program, Pittsburgh, PA 15219 USA
基金
美国国家卫生研究院;
关键词
HMGB1; RAGE; pancreatic cancer; inflammation; mitochondria; ATP; ADVANCED GLYCATION ENDPRODUCTS; GROUP BOX-1 PROTEIN; RAGE; RECEPTOR; CANCER; AUTOPHAGY; MIGRATION; RELEASE; IMMUNE; SIGNAL;
D O I
10.1038/onc.2012.631
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor cells require increased adenosine triphosphate (ATP) to support anabolism and proliferation. The precise mechanisms regulating this process in tumor cells are unknown. Here, we show that the receptor for advanced glycation endproducts (RAGE) and one of its primary ligands, high-mobility group box 1 (HMGB1), are required for optimal mitochondrial function within tumors. We found that RAGE is present in the mitochondria of cultured tumor cells as well as primary tumors. RAGE and HMGB1 coordinately enhanced tumor cell mitochondrial complex I activity, ATP production, tumor cell proliferation and migration. Lack of RAGE or inhibition of HMGB1 release diminished ATP production and slowed tumor growth in vitro and in vivo. These findings link, for the first time, the HMGB1-RAGE pathway with changes in bioenergetics. Moreover, our observations provide a novel mechanism within the tumor microenvironment by which necrosis and inflammation promote tumor progression.
引用
收藏
页码:567 / 577
页数:11
相关论文
共 50 条
  • [31] Effect of Vitamin D on the HMGB1/RAGE Pathway and Adipokines Levels in Obese Asthmatic Mice
    Fan, Yijia
    Chen, Junguo
    Zhu, Xiaofeng
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2023, 22 (03) : 254 - 264
  • [32] HMGB1 promotes hair growth via the modulation of prostaglandin metabolism
    Hwang, Ji-Hye
    Chu, Howard
    Ahn, Yuri
    Kim, Jino
    Kim, Do-Young
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [33] HMGB1 promotes hair growth via the modulation of prostaglandin metabolism
    Ji-Hye Hwang
    Howard Chu
    Yuri Ahn
    Jino Kim
    Do-Young Kim
    Scientific Reports, 9
  • [34] Shizukaol A exerts anti-inflammatory effect by regulating HMGB1/Nrf2/HO-1 pathway
    Tang, Pengfei
    Li, Qiurong
    Liao, Shanting
    Wei, Shanshan
    Cui, Letian
    Xu, Wenjun
    Zhu, Dongrong
    Luo, Jun
    Kong, Lingyi
    PHYTOMEDICINE, 2021, 82
  • [35] ENDOTHELIUM-DERIVED MICROPARTICLES INDUCE RAGE/HMGB1 PATHWAY TO EFFECT LUNG INJURY
    Jeziorczak, P. J.
    Rydlewicz, J. A.
    Kaul, S.
    Pritchard, K. A.
    Oldham, K. T.
    Jacobs, E. R.
    Densmore, J. C.
    SHOCK, 2012, 37 : 109 - 109
  • [36] Rosuvastatin reduces the pro-inflammatory effects of adriamycin on the expression of HMGB1 and RAGE in rats
    Zhang, Haiyan
    Lu, Xiang
    Liu, Zhengxia
    Du, Kang
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 (06) : 3415 - 3423
  • [37] HMGB1 promotes hair growth via the modulation of prostaglandin metabolism
    Hwang, J.
    Chu, H.
    Ahn, Y.
    Kim, D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S156 - S156
  • [38] HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity
    Liao, Yin
    Liu, Shuya
    Fu, Shaozhi
    Wu, Jingbo
    ONCOTARGETS AND THERAPY, 2020, 13 : 6859 - 6871
  • [39] HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response
    Lu, Mudan
    Yu, Shanshan
    Xu, Wei
    Gao, Bo
    Xiong, Sidong
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [40] OGDH promotes the progression of gastric cancer by regulating mitochondrial bioenergetics and Wnt/β-catenin signal pathway
    Lu, Xin
    Wu, Nan
    Yang, Wanli
    Sun, Jia
    Yan, Kemin
    Wu, Jing
    ONCOTARGETS AND THERAPY, 2019, 12 : 7489 - 7500